TY - JOUR KW - Chagas disease KW - Cost effectiveness KW - Chronic Disease KW - Decision Trees KW - Internship and Residency KW - Italy KW - Primary healthcare KW - Quality-Adjusted Life Years KW - public health medicine KW - Health outcomes KW - Health care systems KW - Cost-effectiveness analysis KW - medical residencies KW - Community KW - Sensitivity analysis KW - Treatment effectiveness AU - Marraffa P AU - Marega L AU - Gianino M AB -
Background
Chagas disease is a burdensome condition in non-endemic countries, yet underdiagnosed and underestimated. We aimed to assess cost-effectiveness of alternative screening models in Latin American residents in Italy.
Methods
A decision-analytic model combining a decision tree and a Markov model (annual cycles) was developed to simulate the lifetime progression of chronic disease. Four strategies were compared: usual care (no systematic screening), community-based active screening and two primary care–based approaches (standard and enhanced). Outcomes included costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs) and net monetary benefit (NMB), from a healthcare system perspective, using a €30,000/QALY threshold. Deterministic and probabilistic sensitivity analyses assessed robustness.
Results
Preliminary results estimated that all screening strategies were cost-effective compared with usual care, with ICERs below the threshold. In the base-case analysis, ICERs were €8,397/QALY for active screening, €14,249/QALY for standard primary care and €7,360/QALY for enhanced primary care. Per 10,000 individuals, active screening generated the largest health gains (+101 QALYs) even if with higher incremental costs (€850,478). Deterministic sensitivity analysis was primarily driven by disease prevalence and treatment effectiveness, probabilistic analysis confirmed robustness, with mean ICERs of €24,140/QALY (active screening) and €21,551/QALY (enhanced primary care) and probabilities of cost-effectiveness of 89.1% and 90.1%, respectively.
Conclusions
The lack of systematic screening for Chagas disease in migrants is a missed opportunity to improve health outcomes and resource use. Community-based approaches maximise health gains, while strengthened primary care offers a resource-efficient and scalable option. These findings support the integration of Chagas screening into routine public health and primary care services in Europe.
BT - European Journal of Public Health DA - 10/2026 DO - 10.1093/eurpub/ckag169.394 IS - Supplement_5 LA - ENG M3 - Article N2 -Background
Chagas disease is a burdensome condition in non-endemic countries, yet underdiagnosed and underestimated. We aimed to assess cost-effectiveness of alternative screening models in Latin American residents in Italy.
Methods
A decision-analytic model combining a decision tree and a Markov model (annual cycles) was developed to simulate the lifetime progression of chronic disease. Four strategies were compared: usual care (no systematic screening), community-based active screening and two primary care–based approaches (standard and enhanced). Outcomes included costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs) and net monetary benefit (NMB), from a healthcare system perspective, using a €30,000/QALY threshold. Deterministic and probabilistic sensitivity analyses assessed robustness.
Results
Preliminary results estimated that all screening strategies were cost-effective compared with usual care, with ICERs below the threshold. In the base-case analysis, ICERs were €8,397/QALY for active screening, €14,249/QALY for standard primary care and €7,360/QALY for enhanced primary care. Per 10,000 individuals, active screening generated the largest health gains (+101 QALYs) even if with higher incremental costs (€850,478). Deterministic sensitivity analysis was primarily driven by disease prevalence and treatment effectiveness, probabilistic analysis confirmed robustness, with mean ICERs of €24,140/QALY (active screening) and €21,551/QALY (enhanced primary care) and probabilities of cost-effectiveness of 89.1% and 90.1%, respectively.
Conclusions
The lack of systematic screening for Chagas disease in migrants is a missed opportunity to improve health outcomes and resource use. Community-based approaches maximise health gains, while strengthened primary care offers a resource-efficient and scalable option. These findings support the integration of Chagas screening into routine public health and primary care services in Europe.
PB - Oxford University Press (OUP) PY - 2026 T2 - European Journal of Public Health TI - Cost-effective but underused: evaluating screening strategies for indeterminate Chagas disease UR - https://academic.oup.com/eurpub/article-pdf/36/Supplement_5/ckag169.394/72463033/ckag169.394.pdf VL - 36 SN - 1464-360X ER -